The groups spend big on Terns and Arcellx.
ApexOnco Front Page
Recent articles
J&J’s Tecvayli/Darzalex nod was the second under a new priority voucher scheme.
The group also discontinues a mystery asset, and a Tecentriq trial in periadjuvant lung cancer.
The line-up is revealed to include Merck & Co and J&J itself.
Bristol will test the bispecific in two new lung indications.
A phase 1 study of OKI-219 reads out imminently.
The latest onvansertib data, and an abrupt CEO departure, spook investors.
New pivotal trials of HRS-8080 are planned in first-line and adjuvant breast cancer.
